Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 4;13:1789. doi: 10.1038/s41467-022-29426-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Heatmap showing relative expression of immunoglobulin level of 4d activated B6 FoB with increasing concentration of mitochondrial inhibitors and BSO. High concentration shown in brackets. Statistics are relative to nt. b Left: RT-qPCR of Gclc mRNA in B6 FoB at 0 or 24h after activation in vitro with anti-IgM, CD40 ligand and IL-4. Right: Luminescence-based quantitation of intracellular ROS in resting and 24h stimulated B6 FoB (n = 3 animals examined over two independent experiments). c Titers of IgM (left) and IgG (middle and right) in serum of LCMV Cl13-infected Gclc^fl/fl and Gclc^fl/fl Mb1-Cre⁺ mice as measured by ELISA at the indicated time points (n = 7 animals examined over 3–5 independent experiments). d LCMV Cl13 viral titers in the indicated organs of LCMV Cl13-infected Gclc^fl/fl and Gclc^fl/fl Mb1-Cre⁺ mice as measured by plaque assay at the indicated time points (n = 7 animals examined over 3–5 independent experiments). e Representative contour plot (left) and quantitation (right) of GC B cells (gated as in Supplementary Fig. 1a) in spleens of Gclc^fl/fl and Gclc^fl/fl Mb1-Cre⁺ mice as measured by FACS on day 12 post-LCMV Cl13 infection (n = 3 animals examined over two independent experiments). f Survival curve of Gclc^fl/fl and Gclc^fl/fl Mb1-Cre⁺ mice upon infection with VSV (n = 7 animals examined over two independent experiments). g Titers of neutralizing IgM and/or IgG antibodies against VSV-G protein in serum of Gclc^fl/fl and Gclc^fl/fl Mb1-Cre⁺ mice as measured by ELISA at the indicated time points (n = 7 animals examined over two independent experiments). Dotted/dashed lines represent the detection limit of the assay. For all applicable figure panels, data are mean ± SD and each dot represents one single mouse, except for (a), (c), (d), (f) and (g), where each panel or dot represents the mean of 3–7 mice. In contour plots, numbers represent percentages of the cells gated. Significance (P) was calculated with 2 way ANOVA, except for b and e (unpaired t-test) and f (log-rank test). *P ≤ 0.5; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.